7. New Directions for the 21st Century - 2000s

As 21st century medicine develops in new fields, Nihon Kohden will advance with it. In keeping with its forward looking strategy, in August 2000 Nihon Kohden participated in a short joint venture with Takara Shuzo Co., Ltd. and Wakenyaku Co., Ltd. to market cell therapy related products. In our core areas, we will keep developing the quality and innovative products that our customers all over the world have come to expect.

“World's Firsts" and other notable products by Nihon Kohden

2000 World's first Windows 2000 based EP/EMG system

Neuropack µ MEB-9100 Evoked Potential/EMG Measuring System

Windows® 2000 provides extremely stable operation as well as standard networking, easy operation and compatibility with common software. Neuropack µ is a notebook PC-based unit which is both portable and extremely powerful. Optional hardware and software allow application to different areas of the hospital.

2003 World's first mainstream CO2 sensor for non-intubated patients

Compact CO2 sensor

Nihon Kohden develops the world's first mainstream CO_{2} sensor for non-intubated patients. The unique cap-ONE adaptor catches both oral and nasal breathing. The sensor is compact and lightweight so it is more comfortable for the patient.
This sensor opened a new era in CO_{2} monitoring.

2004 World's first wireless transmitter

ZS-940P transmitter

The world's first wireless monitoring of ECG, respiration, SpO_{2} and NIBP with its ZS-940P transmitter.

2004 World's first wireless EEG

WEE-1000 Wireless EEG Unit

Wireless EEG monitoring gives the patient comfort and freedom of movement. Waveforms are saved in memory on the unit for times when the patient walks out of the receiver range.

Windows is a registered trademark of Microsoft Corporation.

2009 esCCO The next generation of non-invasive hemodynamics monitoring


Nihon Kohden invented a new technology esCCO to non-invasively estimate continuous cardiac output by using ECG and pulse wave data from pulse oxymetry. The trending performance of esCCO to track changes in cardiac output has been evaluated in clinical studies and its accuracy has been shown to be acceptable for clinical use. With esCCO, the quality of hemodynamic monitoring will be improved for all care levels.